Aveo Pharmaceuticals Inc. buy stratec
Start price
21.10.18
/
50%
€22.28
Target price
02.07.19
€37.88
Performance (%)
-72.32%
End price
02.07.19
€6.17
Summary
This prediction ended on 02.07.19 with a price of €6.17. Massive losses of -72.32% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Aveo Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | 0.383% | -1.593% | 16.084% | 14.286% |
| iShares Nasdaq 100 | 1.543% | 7.530% | 38.446% | 53.091% |
| iShares Nikkei 225® | 2.596% | 4.525% | 14.539% | 9.353% |
| iShares S&P 500 | 0.573% | 4.229% | 30.110% | 45.397% |
Comments by stratec for this prediction
In the thread Aveo Pharmaceuticals diskutieren
Being optimistic about AVEO's mid- and long-term potential.
AVEO has a number of shots on deck relating to tivozanib, with possible other catalysts emerging from its nascent drug programs in development. In late 2018 and into 2019, here are some of the items
we can expect:
- Top line data from TIVO-3, which will inform the likelihood of getting approval for tivozanib in the US.
- Submission of a new drug application to the FDA for tivozanib.
- Updated
data from the expansion phase of TiNivo, giving a better sense of the
feasibility and efficacy of the tivozanib-nivolumab combination. - Updates on the development of ficlatuzumab, an HGF scavenger being studied in several solid tumors.
- Initiation of a phase 1 trial for CAN017, a HER3 antibody being developed in partnership with CANbridge Life Sciences in China.
(Vom Mitglied beendet)